Thalidomide Celgene - Important Safety Information from Celgene Europe Limited as approved by the HPRA (June 2016)

Notice type: 3rd Party Publications

Date: 21/06/2016

 

Problem Or Issue:
Important Safety Information communication from Celgene Europe Limited: Thalidomide Celgene - New important advice regarding viral reactivation and pulmonary hypertension.

Important Safety Information - Thalidomide Celgene

 


« Back